Effects of nefiracetam, a novel pyrrolidone-type nootropic agent, on the amygdala-kindled seizures in rats

Epilepsia

Volumn 46, Issue 10, 2005, Pages 1561-1568

  Kitano, Yutaka ^a,c   Komiyama, Chika ^a   Makino, Mitsuhiro ^a   Kasai, Yoshio ^a   Takasuna, Kiyoshi ^a   Kinoshita, Masakazu ^b   Yamazaki, Osamu ^b   Takazawa, Akira ^b   Yamauchi, Toshio ^b   Sakurada, Shinobu ^c  

^a DAIICHI SANKYO CO   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Amygdala; Antiepileptic; Kindling; Levetiracetam; Nefiracetam

Indexed keywords

2 PYRROLIDONE DERIVATIVE; ANTICONVULSIVE AGENT; ETIRACETAM; NEFIRACETAM; NOOTROPIC AGENT; DRUG DERIVATIVE; PIRACETAM;

AFTERDISCHARGE; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; KINDLING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; SEIZURE THRESHOLD; TREATMENT OUTCOME; ANIMAL; ANIMAL BEHAVIOR; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; ELECTRODE; ELECTROSTIMULATION; HUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICS; TEMPORAL LOBE EPILEPSY; WISTAR RAT;

ADMINISTRATION, ORAL; AMYGDALA; ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; ELECTRODES, IMPLANTED; ELECTROENCEPHALOGRAPHY; EPILEPSY, COMPLEX PARTIAL; HUMANS; KINDLING, NEUROLOGIC; MALE; NOOTROPIC AGENTS; PIRACETAM; PYRROLIDINONES; RATS; RATS, WISTAR; SEIZURES;

EID: 27244449904     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.00261.x     Document Type: Article

References (53)

1. Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Rev 1994;19:180-222.
2. Sarter M. Taking stock of cognition enhancers. Trends Pharmacol Sci 1991;12:456-61.
3. Hiramatsu M, Shiotani T, Kameyama T, et al. Effects of nefiracetam on amnesia animal models with neuronal dysfunctions. Behav Brain Res 1997;83:107-15.
4. Nabeshima T, Noda Y, Tohyama K, et al. Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal dysfunctions. Eur J Pharmacol 1990;178:143-9.
5. A and muscarinic receptors induced by cyclohexamide. J Pharmacol Exp Ther 1991;257:271-5.
6. Sakurai T, Ojima H, Yamasaki T, et al. Effects of α-(2,6- dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide (DM-9384) on learning and memory in rats. Jpn J Pharmacol 1989;50:47-53.
7. Yoshii M, Watabe S. Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells. Brain Res 1994;642:123-31.
8. Yoshii M, Watabe S, Sakurai T, et al. Cellular mechanisms underlying cognition-enhancing actions of nefiracetam (DM-9384). Behav Brain Res 1997;83:185-8.
9. Abe E. Reversal effect of DM-9384 on scopolamine-induced acetylcholine depletion in certain regions of the mouse brain. Psychopharmacology (Berl) 1991;105:310-6.
10. Abe E, Murai S, Saito H, et al. Effects of nefiracetam, a novel pyrrolidone derivative, on brain monoamine metabolisms in mice. J Neural Transm (Gen Sect) 1992;90:125-36.
11. Kawajiri S, Taniguchi K, Sakurai T, et al. Nefiracetam enhances acetylcholine outflow from the frontal cortex: in vivo microdialysis study in the rat. J Neural Transm (Gen Sect) 1994;98:15-22.
12. Sakurai T, Kato T, Mori K, et al. Nefiracetam elevates extracellular acetylcholine level in the frontal cortex of rats with cerebral cholinergic dysfunctions: an in vivo microdialysis study. Neurosci Lett 1998;246:69-72.
13. Watabe S, Taniguchi K, Kojima H. Improvement of impaired brain monoamine metabolism by the cognition-enhancing agent nefiracetam after microsphere-induced cerebral embolism in rats. Arzneimittelforschung 1994;44:195-8.
14. Watabe S, Yamaguchi H, Ashida S. DM-9384, a new cognitionen-hancing agent, increases the turnover of components of GABAergic system in the rat cerebral cortex. Eur J Pharmacol 1993;238:303-9.
15. Hawkins CA, Mellanby JH. Piracetam potentiates the antiepileptic action of carbamazepine in chronic experimental limbic epilepsy. Acta Neurol Scand 1986;74(suppl 109):117-21.
16. Mondadori C, Schmutz M. Synergistic effects of oxiracetam and piracetam in combination with antiepileptic drugs. Acta Neurol Scand 1986;74(suppl 109):113-6.
17. Schmidt J. Comparative studies on the anticonvulsant effectiveness of nootropic drugs in kindled rats. Biomed Biochim Acta 1990;49:413-9.
18. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002;51:31-71.
19. Shorvon S. Pyrrolidone derivatives. Lancet 2001;358:1885-92.
20. Uthman BM, Reichl A. Progressive myoclonic epilepsies. Curr Treat Options Neurol 2002;4:3-17.
21. Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2000;2:99-105.
22. Gower AJ, Noyer M, Verloes R, et al. Ucb L059, a novel anticonvulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992;222:193-203.
23. Klitgaard H, Matagne A, Gobert J, et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998;353:191-206.
24. Löscher W, Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993;232:147-58.
25. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-42.
26. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004;291:605-14.
27. Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures: European Levetiracetam Study Group. Epilepsia 2000;41:1179-86.
28. Kitano Y, Komiyama C, Makino M, et al. Anticonvulsant properties of the novel nootropic agent nefiracetam in seizure models of mice and rats. Epilepsia 2005;46:811-18.
29. Kitano Y, Makino M, Usui C, et al. General pharmacological profile of the new cognition-enhancing agent nefiracetam. Arzneimittelforschung 1994;44:199-210.
30. Nakamoto Y, Shiotani T, Watabe S, et al. Nootropic nefiracetam inhibits proconvulsant action of peripheral-type benzodiazepines in epileptic mutant EL mice. Ann N Y Acad Sci 2004;1025:135-9.
31. Shiotani T, Nakamoto Y, Watabe S, et al. Anticonvulsant actions of nefiracetam on epileptic EL mice and their relation to peripheral-type benzodiazepine receptors. Brain Res 2000;859:255-61.
32. Hashizume K, Kunimoto M, Maeda T, et al. Antiepileptic effect of nefiracetam on kainic acid-induced limbic seizure in rats. Epilepsy Res 2000;39:221-8.
33. Tanaka T, Hashizume K, Sawamura A, et al. Basic science and epilepsy: experimental epilepsy surgery. Stereotact Funct Neurosurg 2001;77:239-44.
34. McNamara JO. Kindling: an animal model of complex partial epilepsy. Ann Neurol 1984;16(suppl):S72-6.
35. Sato M, Racine RJ, McIntyre DC. Kindling: basic mechanisms and clinical validity. Electroencephalogr Clin Neurophysiol 1990;76:459-72.
36. Löscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998;284:474-9.
37. Stratton SC, Large CH, Cox B, et al. Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model. Epilepsy Res 2003;53:95-106.
38. Takazawa A, Yamazaki O, Kinoshita M, et al. Nefiracetam, a new nootropic agent, has potent anticonvulsant effects on amygdaloid kindled seizures of rats. Epilepsia 1999;40(suppl 2):131.
39. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Sydney: Academic Press, 1986.
40. Freeman FG, Jarvis MF. The effect of interstimulation interval on the assessment and stability of kindled seizure thresholds. Brain Res Bull 1981;7:629-33.
41. Racine RJ. Modification of seizure activity by electrical stimulation, II: motor seizure. Electroencephalogr Clin Neurophysiol 1972;32:281-94.
42. Giurgea CE. The nootropic concept and its prospective implications. Drug Dev Res 1982;2:441-6.
43. Aihara H, Li X, Fujiwara S, et al. The protective action of nefiracetam against electrophysiological and metabolic damage in the hippocampus after deprivation of glucose and oxygen. Brain Res 2001;922:158-62.
44. Fujita R, Takayama N, Ueda H. The cognition-enhancer nefiracetam is protective in BDNF-independent neuronal cell death under the serum-free condition. Neurochem Int 2002;40:139-43.
45. Ueda M, Fujita R, Koji T, et al. The cognition-enhancer nefiracetam inhibits both necrosis and apoptosis in retinal ischemic models in vitro and in vivo. J Pharmacol Exp Ther 2004;309:200-7.
46. Hasegawa M, Nakayama S, Kinoshita H, et al. Effects of the subacute administration of nefiracetam on abnormal behavior in aged rats. Behav Brain Res 1996;78:93-100.
47. Rashid MH, Ueda H. Nonopioid and neuropathy-specific analgesic action of the nootropic drug nefiracetam in mice. J Pharmacol Exp Ther 2003;303:226-31.
48. Weiss SR, Post RM. Kindling: separate vs. shared mechanisms in affective disorders and epilepsy. Neuropsychobiology 1998;38:167-80.
49. Hamada K, Song HK, Ishida S, et al. Contrasting effects of zonisamide and acetazolamide on amygdaloid kindling in rats. Epilepsia 2001;42:1379-86.
50. Weiss SR, Post RM. Carbamazepine and carbamazepine-10,11-epoxide inhibit amygdala-kindled seizures in the rat but do not block their development. Clin Neuropharmacol 1987;10:272-9.
51. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004;101:9861-6.
52. Madeja M, Margineanu DG, Gorji A, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003;45:661-71.
53. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002;43:9-18.